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Abstract Activation of p38 or p44/42 mitogen-activated protein
(MAP) kinases has been shown to trigger differentiation in a
number of cell types. The present study has investigated the roles
of these kinases in the K-melanocyte stimulating hormone (K-
MSH)-induced melanogenic and proliferative responses in B16
melanoma cells. Treatment of cells with K-MSH led to the time-
dependent phosphorylation of both p38 and p44/42 MAP
kinases. However, only inhibition of p38 MAP kinase activity
with SB 203580 blocked both the K-MSH-induced melanogenic
and anti-proliferative effects. It therefore appears that activation
of the p38 pathway can promote melanogenesis and inhibit
growth of B16 melanoma cells. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
K-Melanocyte stimulating hormone (K-MSH) is a trideca-
peptide which is derived from corticotrophin, a cleavage prod-
uct of the larger precursor proopiomelanocortin [1]. K-MSH
exerts its e¡ects through interaction with a family of ¢ve hep-
tahelical, G protein-coupled receptors (MC1^MC5) which
have a wide range of e¡ects in the skin, as well as the central
nervous and immune systems [1^3]. Melanocortin receptors
have been identi¢ed on the surface of both melanocytes and
melanoma cells, as detected by ligand-conjugated beads and
£uorescent markers [4,5]. The ¢nding that melanoma cells are
able to secrete autocrine K-MSH [6], coupled with the fact
that patients with malignant melanoma have elevated plasma
K-MSH levels [2], suggests that this hormone may be involved
in the pathophysiology of melanoma. A number of agents,
including cholera toxin, forskolin, K-MSH, and ultraviolet
(UV) light, have been reported to trigger melanoma/melano-
cyte di¡erentiation [7^11], a process which involves both den-
drite outgrowth and the activation of melanin production
(melanogenesis) [8^10,12].
A growing number of G protein-coupled receptors have
been shown to exert their e¡ects via activation of the mito-
gen-activated protein (MAP) kinases [13]. The p44/42 MAP
kinases are activated almost universally in response to growth
factors and can either phosphorylate cytoplasmic targets or
translocate to the nucleus, where they activate transcription
factors such as Elk-1 and SAP-2 [14]. Other members of the
MAP kinase family, such as p38 or the stress-activated protein
kinases, are stimulated by in£ammatory cytokines and envi-
ronmental stresses leading to apoptosis or di¡erentiation [15^
17]. At present, little is known about the ability of melano-
cortin receptors to activate either p38 or p44/42 MAP kinases.
The aim of the present study was to examine the role of these
MAP kinases in the growth and di¡erentiation of B16 murine
melanoma cells, which are known to endogenously express
MC1 receptors [18].
2. Materials and methods
2.1. p38 and p44/42 MAP kinase stimulation studies
Unless otherwise stated, all reagents were from Sigma (Dorset,
UK). B16 murine melanoma cells (obtained from Drs Ulrike Sahm
and Colin Pouton, School of Pharmacy and Pharmacology, Univer-
sity of Bath) were seeded at a density of 100 000 cells per well into six-
well plates (Falcon) and incubated overnight in RPMI 1640 media
(Autogen BioClear, Wiltshire, UK) supplemented with 10% foetal
calf serum, penicillin (5000 IU), streptomycin (50 Wg ml31) and L-
glutamine (2 mM). In time-course studies, K-MSH (Calbiochem,
UK) (10 nM) or forskolin (10 WM) was added to B16 melanoma cells
for increasing periods of time (4^120 min). Experiments were termi-
nated by aspiration of the media and the addition of ice-cold phos-
phate-bu¡ered saline. In some studies, cells were treated with inhib-
itors (all Calbiochem, UK) of either p38 MAP kinase (SB 203580, 10
WM), MEK1 (PD 98059, 10 WM), protein kinase C (PKC) (Ro 31-
8220, 2 WM), or phosphoinositide (PI) 3-kinase (LY 294002, 10 WM),
for 30 min, prior to addition of either K-MSH (10 nM), or phorbol-
12-myristate-13-acetate (TPA, 500 nM) for 10 min.
2.2. Western analysis
Cells were solubilised in 200 Wl SDS^PAGE sample bu¡er (4%
sodium dodecyl sulphate (SDS), 60 mM Tris pH 6.8, 5% glycerol,
0.01% bromophenol blue and 50 mM mercaptoethanol), diluted
with 400 Wl distilled water and heated to 95‡C for 5 min. Whole
cell protein extracts were separated on 10% SDS-polyacrylamide
gels. Proteins were electrophoretically transferred onto PVDF mem-
branes (Millipore) overnight, washed in Tris-bu¡ered saline (TBS; 100
mM Tris^HCl, pH 7.5 and 150 mM NaCl), before being blocked in
TBS containing 0.1% Tween-20 and 5% milk (TBST-milk). Antibody
incubations were for 1 h at 21‡C in TBST-milk with either anti-phos-
pho speci¢c p38 or anti-phospho speci¢c p44/p42 MAP kinase anti-
bodies as the primaries (both 1:1000 dilutions, from New England
Biolabs), followed by an anti-rabbit horseradish peroxidase-conju-
gated secondary antibody (New England Biolabs). Immunocomplexes
were visualised using the enhanced chemiluminescence (ECL) system
(Amersham Pharmacia Biotech, UK) and detected on photographic
¢lm (Kodak, UK). In order to con¢rm equal protein loading, blots
were stripped by treatment for 1 h in stripping bu¡er (50‡C, 0.1 M
mercaptoethanol, 62.5 mM Tris^HCl). Blots were then washed three
times in TBST and blocked in TBST-milk followed by incubation
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with an anti-K-tubulin antibody (Sigma, UK). Blots were then visual-
ised by ECL, as described previously. In some studies, equal protein
loading was con¢rmed by staining blots with Coomassie blue solution
(0.1% Coomassie brilliant blue, 45% methanol, 10% acetic acid), fol-
lowed by destaining (45% methanol, 10% acetic acid).
2.3. Melanogenesis studies
Extracellular melanin release was measured as previously described
[19]. Brie£y, B16 cells were seeded at a density of 5U104 cells per ml
into six-well plates and incubated overnight, before the administration
of increasing concentrations of K-MSH (0.1 nM^1 WM). Plates were
then incubated for 72 h, after which 100 Wl of the media was taken
and read spectrophotometrically at 404 nm using a plate reader. Cells
were then scraped from the plates and re-suspended in cell culture
media containing trypan blue (¢nal concentration 0.1% w/v) and
counted using a haemocytometer. Mean increases in extracellular mel-
anin production per cell were expressed as a percentage of basal
melanin production in control cells. In some studies, cells were treated
with inhibitors of PKC (Ro 31-8220 at 2 WM), PI 3-kinase (LY 294002
at 10 WM), MEK1 (PD 98059, at 10 WM) or p38 (SB 203580, at 10
WM) for 30 min prior to the addition of K-MSH (10 nM). Control
experiments were also performed where cells were incubated with ki-
nase inhibitors alone (as above).
2.4. Growth inhibition studies
Cells were seeded at a density of 5U104 cells per ml into six-well
plates and incubated overnight before being treated with either inhib-
itors of PKC (Ro 31-8220 at 2 WM), PI 3-kinase (LY 294002, at 10
WM), MEK1 (PD 98059, at 10 WM) or p38 MAP kinase (SB 203580,
at 10 WM) for 30 min prior to the addition of K-MSH (10 nM).
Control wells were either treated with K-MSH only, or received no
drug treatment. In other studies, individual wells were incubated with
increasing concentrations of K-MSH (0.1 nM^1 WM) in the absence or
presence of SB 203580 (10 WM). In all experiments, plates were left to
incubate for 72 h and cells were removed by scraping. Cells were
centrifuged and re-suspended in cell culture media containing trypan
blue (¢nal concentration 0.1% w/v) and were counted using a haemo-
cytometer.
2.5. Statistical analysis
Unless otherwise stated all results are taken from three experiments
performed in duplicate þ S.E.M. All pEC50 values were determined
from individual experiments by non-linear regression, using a four-
parameter logistic equation (GraphPad Prism). Results were analysed
using Student’s t-test and noted to be signi¢cantly di¡erent where
P6 0.05.
3. Results
Treatment of B16 melanoma cells with K-MSH (10 nM)
induced a time-dependent stimulation of p38 MAP kinase
(Fig. 1A). Increases in p38 MAP kinase activity were slow
in onset with increases in activity not being detected until 60
min after stimulation. Equal loading of protein samples was
con¢rmed by stripping of the original blots and detection with
an anti-K-tubulin antibody (Fig. 1B). Exposure of cells to
increasing concentrations of K-MSH (0.1 nM^1 WM for 60
min) led to a concentration-dependent increase in p38 MAP
kinase phosphorylation (Fig. 1C). Pre-treatment of cells with
the MEK1 inhibitor (PD 98059, 10 WM) or PI 3-kinase inhib-
itor (LY 294002, 10 WM) were found to potentiate the K-
MSH-induced phosphorylation of p38 MAP kinase (Fig.
1D). In contrast, pre-treatment with the PKC inhibitor (Ro
31-8220, 2 WM) did not signi¢cantly alter the ability of K-
MSH to activate p38 MAP kinase. In other studies, treatment
of cells with the adenylyl cyclase activator forskolin (10 WM)
was shown to activate p38 MAP kinase (Fig. 1E), with in-
creases in phosphorylation only being detected after 120 min
of drug treatment (Fig. 1E). In contrast to p38 MAP kinase,
K-MSH was shown to rapidly activate p44/42 MAP kinase (4
min) in a concentration-dependent manner for sustained peri-
ods of time (s 120 min) (data not shown). Treatment of B16
cells with the protein kinase C activator, TPA, 500 nM, was
also shown to activate p44/42 MAP kinase (data not shown).
In this instance, pre-treatment cells with PD-98059 and Ro
Fig. 1. A: Time-course (in min) of the K-MSH-stimulated phosphor-
ylation of p38 MAP kinase in B16 cells. Cells were incubated in the
presence of K-MSH for the times shown in min and then analysed
using Western blotting using an antibody speci¢c for the dually
phosphorylated forms of p38 MAP kinase (Thr180 and Tyr182). The
blot is representative of three separate experiments, and represents a
single immunoblot. B: Re-probe of the blot from A, demonstrating
equal protein loading. The blot from A was stripped and probed
with an antibody speci¢c for K-tubulin. C: K-MSH-stimulated phos-
phorylation of p38 MAP kinase in B16 murine melanoma cells.
Cells were incubated in the presence of increasing concentrations of
K-MSH (60 min) and analysed using Western blotting using an anti-
body speci¢c for the dually phosphorylated forms of p38 MAP ki-
nase (Thr180 and Tyr182). The blot is representative of three separate
experiments, and represents a single immunoblot. D: E¡ect of vari-
ous kinase inhibitors on K-MSH-induced phosphorylation of p38
MAP kinase in B16 cells. Cells were incubated in the presence of K-
MSH or absence (labelled control) for 60 min either with or without
pre-incubation with PD 98059 (PD, 10 WM), LY 294002 (LY, 10
WM) and Ro 31-8220 (Ro, 2 WM) (all 30 min) then analysed using
Western blotting using an antibody speci¢c for the dually phosphor-
ylated forms of p38 MAP kinase (Thr180 and Tyr182). The blot is
representative of three separate experiments and represents a single
immunoblot. E: Time-course (in min) of the forskolin-stimulated
phosphorylation of p38 MAP kinase in B16 cells. Cells were incu-
bated in the presence of forskolin (10 WM) for the times shown in
min and then analysed using Western blotting using an antibody
speci¢c for the dually phosphorylated forms of p38 MAP kinase
(Thr180 and Tyr182). The blot is representative of three separate ex-
periments and represents a single immunoblot.
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31-8220, but not LY 294002, were shown to block the TPA-
induced p44/42 MAP kinase activation.
Studies were undertaken to determine the involvement of
p38 and p44/42 MAP kinases in the K-MSH-mediated stim-
ulation of melanogenesis. Addition of increasing concentra-
tions of K-MSH increased the amount of melanin detected
in the extracellular media, as measured by spectrophotometry
(Fig. 2). In the absence of K-MSH, absorbance levels were
0.25 þ 0.02 AU (wavelength: 404 nm), which increased to
0.54 þ 0.03 AU after a 72 h treatment with K-MSH (10
nM). After correction for cell number, K-MSH (10 nM) in-
duced signi¢cant (P6 0.05) increases in extracellular melanin
equivalent to 243 þ 17% of basal melanin production. Pre-
treatment of cells with either the protein kinase C inhibitor,
Ro 31-8220, or the p38 MAP kinase inhibitor, SB 203580, led
to signi¢cant (P6 0.05) reductions in K-MSH-induced extra-
cellular melanin accumulation to 140 þ 14% and 137 þ 13% of
basal melanin release, respectively (Fig. 2). This was in con-
trast to pre-treatment of the cells with either PD 98059 or
LY-294002 which signi¢cantly (P6 0.05) increased levels of
K-MSH-induced melanin production to 338 þ 36% and
4411 þ 558% of basal extracellular melanin levels per cell, re-
spectively. In control studies it was found that administration
of PD 98059 or LY 294002 alone signi¢cantly (P6 0.05) in-
creased extracellular melanin production per cell to 418 þ 69%
and 1288 þ 140% of basal values, respectively. However, incu-
bation of cells with either Ro 31-8220 or SB 203580 alone did
not signi¢cantly alter levels of extracellular melanin.
In order to investigate the role of p38 MAP kinase in the K-
MSH-induced melanogenic response, concentration^e¡ect
curves to K-MSH were generated in the absence and presence
of SB 203580 (10 WM). In the absence of SB 203580, K-MSH
was highly potent at inducing melanin production (pEC50 of
9.20 þ 0.05) (Fig. 3), whereas in the continuous presence of SB
203580 the K-MSH-induced increases in extracellular melanin
were signi¢cantly inhibited (P6 0.05).
The e¡ects of K-MSH upon cell growth were examined by
directly counting viable cells using a trypan blue exclusion
protocol. In the absence of drug, incubation of cells for 72 h
gave mean cell counts of 2.02 þ 0.09U106 cells/well. Treat-
ment of cells with K-MSH (10 nM) led to a signi¢cant
(P6 0.05) reduction in cell numbers of 33.0 þ 1.0% relative
to control values (Fig. 4). Pre-treatment of cells with PD
98059 (10 WM) or LY 294002 (10 WM), had inhibitory e¡ects
on cell growth that were more marked than K-MSH alone;
reducing cell numbers by 74.3 þ 4.5% and 91.8 þ 1.4% of con-
trol values, respectively (Fig. 4). Other studies showed that
administration of PD 98059 or LY-294002 alone led to a
signi¢cant (P6 0.05) reduction in cell growth to 53.2 þ 2.3%
and 90.2 þ 1.6% of control values, respectively. In contrast,
treatment of the cells with the PKC inhibitor, Ro 31-8220,
had no signi¢cant e¡ect upon on the inhibition of growth
mediated by K-MSH, but did induce a slight proliferative
e¡ect when applied alone equivalent to 127.3 þ 7.8% of basal
growth. Pre-treatment of the cells with the p38 MAP kinase
inhibitor, SB 203580 (10 WM), blocked the anti-proliferative
e¡ect seen in response to increasing concentrations of K-MSH.
Fig. 2. Percentage increase in extracellular melanin production in re-
sponse to K-MSH (10 nM) in B16 melanoma cells, in the absence
and presence of PD-98059 (PD, 10 WM), LY 294002 (LY, 10 WM)
Ro 31-8220 (Ro, 2 WM) or SB 203580 (SB, 10 WM). Increases in ab-
sorbance were measured spectrophotometrically (at 404 nm) and ex-
pressed as a percentage of basal melanin release per cell. Data show
the mean þ S.E.M. of three experiments performed in duplicate.
Fig. 3. Increases in extracellular melanin accumulation in response
to increasing concentrations of K-MSH, in the absence (8) and
presence (F) of SB 203580 (10 WM). Increases in absorbance were
measured spectrophotometrically (at 404 nm) and expressed as a
percentage of basal melanin release per cell. Data show the mean þ
S.E.M. of three experiments performed in duplicate.
Fig. 4. The e¡ects of K-MSH and various kinase inhibitors upon
B16 melanoma cell growth. Data show cell growth after 72 h in un-
treated cells (Control), cells treated with K-MSH (10 nM) and cells
in the continuous presence of either PD 98059 (PD, 10 WM), LY
294002 (LY, 10 WM), Ro-31 8220 (Ro, 2 WM) or SB 203580 (SB,
10 WM) followed by K-MSH treatment (10 nM). Cell numbers were
expressed as a percentage of control cell growth. Data show mean þ
S.E.M. of three experiments performed in duplicate.
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Incubation of B16 cells in the continuous presence of increas-
ing concentrations of K-MSH led to concentration-dependent
inhibition of cell growth (Fig. 5). Maximal inhibition reduced
cell numbers to 47.9 þ 4.1% of control cell growth (pIC50 of
8.22 þ 0.08) (Fig. 5). However in the continuous presence of
SB 203580 (10 WM) the K-MSH-induced inhibition of B16 cell
growth was abolished. It was further noted that incubation of
cells with SB 203580 alone had no signi¢cant e¡ects upon
growth.
4. Discussion
Activation of the p38 and p44/42 MAP kinases has been
shown to trigger cell di¡erentiation [16,17,20]. Recent work
has demonstrated that both forskolin and K-MSH activate
p44/42 MAP kinase in B16 melanoma cells [21,22]. However,
little is known about the ability of these agents to stimulate
p38 MAP kinase. The aim of the present study was to inves-
tigate whether K-MSH activated p38 MAP kinase and
whether the evoked activity of p38 and p44/42 MAP kinases
were involved in B16 melanoma-induced melanogenesis or
proliferation.
Administration of K-MSH induced a time-dependent in-
crease in the phosphorylation of p38 MAP kinase, which
was much slower in onset than that of p44/42 MAP kinase.
Treatment of B16 cells with the adenylyl cyclase activator,
forskolin, also induced a time-dependent increase in p38
MAP kinase activation, with a similar kinetic pro¢le as that
of K-MSH. Previous studies have demonstrated that forskolin
can induce melanin production in B16 melanoma cells inde-
pendently of G-protein activation [12]. This may suggest that
the K-MSH-induced stimulation of p38 kinase is downstream
of adenylyl cyclase activation. Pre-treatment of cells with in-
hibitors of MEK1 and PI 3-kinase were found to potentiate
the K-MSH-induced stimulation of p38 MAP kinase, suggest-
ing that there may be some feedback between PI 3-kinase/p44/
42 MAP kinase inhibition and p38 MAP kinase activation.
A primary aim of this study was to determine the role of
p38 and p44/42 MAP kinases in B16 cell di¡erentiation. Upon
di¡erentiation, melanoma cells undergo morphological
changes, and induce melanin production [8^10,12]. This study
has utilised the accumulation of extracellular melanin as a
marker of B16 di¡erentiation. In common with previous
work [7,19,28], it was demonstrated that administration of
K-MSH induced signi¢cant levels of extracellular melanin in
the media of B16 cells. Pre-treatment with the p38 inhibitor,
SB 203580, abolished the K-MSH-induced increases in extra-
cellular melanin accumulation, implicating the involvement of
p38 in the K-MSH-induced melanogenic response. Melano-
genesis is a multistage process involving melanin synthesis,
melanosome transport to dendrite tips and melanosome re-
lease. As this study has looked at extracellular melanin accu-
mulation only we have been unable to determine the stage(s)
of melanogenesis which involve p38 MAP kinase activation.
Pre-treatment of cells with inhibitors of either PI 3-kinase (LY
294002) or MEK1 (PD 98059) were found to potentiate the K-
MSH-induced increases in extracellular melanin. Moreover,
when cells were treated with either PD 98059 or LY 294002
alone, signi¢cant melanogenesis was induced, possibly indicat-
ing that these pathways were constitutively active and nega-
tively regulating melanogenesis. These ¢ndings agree with pre-
vious studies that have also shown that inhibition of either the
PI 3-kinase or p44/42 MAP kinase pathways induced melanin
production in B16 melanoma cells [12,21].
The observed increases in K-MSH-stimulated extracellular
melanin accumulation were found to be signi¢cantly inhibited
following pre-treatment with the PKC inhibitor, Ro 31-8220.
Di¡erentiation of B16 melanoma cells, as measured by the K-
MSH-induced melanogenic response has been shown previ-
ously to be PKC-dependent, in that both PKC downregula-
tion via treatment with phorbol esters [23] and PKC inhibitors
such as calphostin C, were found to block K-MSH-induced
melanogenesis [24]. The concentration of Ro 31-8220 (2 WM)
used in these studies were demonstrated to partially inhibit
TPA-induced p44/42 MAP kinase phosphorylation. Concen-
trations of Ro 31-8220 in excess of 2 WM were not used as
they were found to a¡ect the ability of B16 cells to adhere to
tissue culture plates (unpublished observations).
Treatment of B16 melanoma cells for 72 h with K-MSH led
to a concentration-dependent inhibition of cell growth. Time-
course studies revealed that cell growth was not signi¢cantly
inhibited until after 48 h of K-MSH treatment (unpublished
observations), suggesting that K-MSH treatment was not in-
ducing apoptosis in this cell line. The actions of K-MSH upon
melanoma growth are subject to controversy, with both pro-
liferative [25,26] and anti-proliferative e¡ects [27,28] being re-
ported. It has been suggested that the anti-proliferative e¡ects
of K-MSH are a result of melanogenesis being induced, and
the subsequent accumulation of toxic melanin by-products
[25]. There is, however, evidence that other factors may be
involved; in amelanotic Bomirski hamster melanoma cells,
K-MSH inhibits cell growth independently of melanogenesis
[26]. Furthermore, studies using B16 melanoma cells, have
shown that the naturally occurring K-MSH antagonist, agouti
protein, is able to antagonise melanogenesis as well as inhib-
iting cell growth in a similar manner as K-MSH [29]. Pre-
treatment of B16 cells with SB 203580 in this study, abolished
the anti-proliferative e¡ect of K-MSH, and suggests for the
¢rst time that p38 MAP kinase may be involved in mediating
this e¡ect. Further evidence for the involvement of p38 MAP
kinase in these processes comes from studies demonstrating
that agents which induce B16 cell di¡erentiation, such as for-
Fig. 5. Inhibition of B16 melanoma growth in response to increas-
ing concentrations of K-MSH. Cells were incubated with increasing
concentrations of K-MSH in the absence (8) and presence (F) of
SB 203580 (10 WM), for 72 h. Cell numbers were expressed as a per-
centage of control cell growth. Data shows mean þ S.E.M. of three
experiments performed in duplicate.
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skolin, LY 294002 and PD 98059 also activate p38 MAP ki-
nase in these cells. Although p38 MAP kinase seems to be
involved in both the anti-proliferative and melanogenic e¡ects
of K-MSH, a di¡erential requirement seems to be needed for
PKC. Treatment of cells with the PKC inhibitor, Ro 31-8220,
was found to have no signi¢cant e¡ect upon the inhibition of
cell proliferation by K-MSH. This would suggest that a build-
up of melanin or toxic products by these cells does not con-
tribute signi¢cantly to an anti-proliferative function. How-
ever, studies on basal melanocyte growth have shown that
PKC down-regulation (by phorbol ester treatment) is prolif-
erative [11,30,31].
Treatment of cells with either PD 98059 or LY 294002
potentiated the K-MSH-mediated anti-proliferative e¡ect. In-
deed, when either agent was added alone there were marked
inhibitory e¡ects on cell growth; suggesting that these path-
ways may be constitutively active in melanoma cells.
Melanocyte di¡erentiation and proliferation are believed to
be opposing cellular phenomena. In melanocytes, di¡erentia-
tion induced by UV light is accompanied by G1 cell-cycle
arrest, via the expression of cyclin-dependent kinase inhibitor
p21Wafÿ1=SDÿ1=Cipÿ1 [9]. An intriguing ¢nding of the present
study is that the anti-proliferative activity of K-MSH corre-
lated with p38 activation and not with that of p44/42 MAP
kinases. Previous studies on 3T3-L1 [32] and ATDC5 cells [17]
in which both p44/42 and p38 MAP kinase were simultane-
ously active showed that inhibition of p38 alone blocked dif-
ferentiation. Moreover, in common with the present study,
administration of PD 98059 alone was su⁄cient to induce
di¡erentiation in ATDC5 cells [17].
In summary, we have demonstrated for the ¢rst time that K-
MSH activates p38 MAP kinase in B16 murine melanoma
cells. Furthermore, activation of p38 MAP kinase by K-
MSH may be important for both its anti-proliferative e¡ects
and the production of melanin.
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